Medical Device | December 01, 2021
Roche completes acquisition of TIB Molbiol
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
It’s a two-dose vaccine administered 28 days apart
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Subscribe To Our Newsletter & Stay Updated
